FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080686927> ?p ?o ?g. }

• W2080686927 endingPage "172" @default.
• W2080686927 startingPage "162" @default.
• W2080686927 abstract "The purpose of the study was to investigate the physical state of hot-melt extruded guaifenesin tablets containing either Acryl-EZE® or Eudragit L100-55® and to study the physicochemical factors influencing crystal growth of guaifenesin on the surface of the extrudates. The powder mixtures containing Acryl-EZE® were extruded on a single-screw Randcastle Microtruder at 20 rpm and at temperatures of 90, 95, 110 °C (zones 1, 2, 3, respectively) and 115 °C (die), before being manually cut into tablets (250 ± 5 mg). Extrudates containing Eudragit L100-55®, TEC and guaifenesin were extruded at temperatures ranging from 60 to 115 °C. Modulated differential calorimetry (DSC) was used to demonstrate the plasticizing effect of guaifenesin on Eudragit L100-55®. Powder X-ray diffraction (PXRD) showed that while the drug powder is crystalline, extrudates containing up to 25% drug exhibited an amorphous diffraction profile. Extrudates containing higher drug concentrations showed an amorphous profile with some crystalline peaks corresponding to guaifenesin, indicating that the limit of solubility of drug in the matrix had been exceeded. Scanning electron microscopy was used to demonstrate that drug crystallization was a surface phenomenon and dependent on the drug concentration. In vitro dissolution testing showed no effect of surface crystallization of guaifenesin on drug release rates of extruded matrix tablets. The influence of hydrophilic polymeric additives including PVP K25, polycarbophil, PEG 3350, poloxamer 188 or poly(ethylene oxide) as crystal growth inhibitors was investigated at a level of 10% based on the drug content. The extent of crystal growth was reduced for all additives. Complete drug release in pH 6.8 phosphate buffer was prolonged from 4 h in extrudates containing Acryl-EZE® and guaifenesin to 8 h in extrudates containing Eudragit L100-55®, TEC and guaifenesin. Drug release in extrudates containing Eudragit L100-55® and guaifenesin was not affected by the presence of hydrophilic additives present at 10% based on the drug content. In vitro drug release studies showed no significant change during storage for up to 6 months at 25 °C/60% relative humidity and 40 °C/75% relative humidity." @default.
• W2080686927 created "2016-06-24" @default.
• W2080686927 creator A5026372655 @default.
• W2080686927 creator A5034805665 @default.
• W2080686927 creator A5035051859 @default.
• W2080686927 creator A5085391765 @default.
• W2080686927 date "2007-08-01" @default.
• W2080686927 modified "2023-10-16" @default.
• W2080686927 title "Crystal growth formation in melt extrudates" @default.
• W2080686927 cites W1525207856 @default.
• W2080686927 cites W1975447565 @default.
• W2080686927 cites W1990663620 @default.
• W2080686927 cites W1992610932 @default.
• W2080686927 cites W2006657575 @default.
• W2080686927 cites W2012645834 @default.
• W2080686927 cites W2017025004 @default.
• W2080686927 cites W2018999993 @default.
• W2080686927 cites W2023049080 @default.
• W2080686927 cites W2023333312 @default.
• W2080686927 cites W2029023434 @default.
• W2080686927 cites W2031415962 @default.
• W2080686927 cites W2038171005 @default.
• W2080686927 cites W2055126493 @default.
• W2080686927 cites W2056148809 @default.
• W2080686927 cites W2060349135 @default.
• W2080686927 cites W2060486968 @default.
• W2080686927 cites W2064572156 @default.
• W2080686927 cites W2066122550 @default.
• W2080686927 cites W2075502309 @default.
• W2080686927 cites W2075954364 @default.
• W2080686927 cites W2078858223 @default.
• W2080686927 cites W2087969058 @default.
• W2080686927 cites W2116011637 @default.
• W2080686927 doi "https://doi.org/10.1016/j.ijpharm.2007.04.008" @default.
• W2080686927 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17524578" @default.
• W2080686927 hasPublicationYear "2007" @default.
• W2080686927 type Work @default.
• W2080686927 sameAs 2080686927 @default.
• W2080686927 citedByCount "44" @default.
• W2080686927 countsByYear W20806869272012 @default.
• W2080686927 countsByYear W20806869272013 @default.
• W2080686927 countsByYear W20806869272014 @default.
• W2080686927 countsByYear W20806869272015 @default.
• W2080686927 countsByYear W20806869272016 @default.
• W2080686927 countsByYear W20806869272017 @default.
• W2080686927 countsByYear W20806869272018 @default.
• W2080686927 countsByYear W20806869272019 @default.
• W2080686927 countsByYear W20806869272021 @default.
• W2080686927 countsByYear W20806869272022 @default.
• W2080686927 crossrefType "journal-article" @default.
• W2080686927 hasAuthorship W2080686927A5026372655 @default.
• W2080686927 hasAuthorship W2080686927A5034805665 @default.
• W2080686927 hasAuthorship W2080686927A5035051859 @default.
• W2080686927 hasAuthorship W2080686927A5085391765 @default.
• W2080686927 hasConcept C121332964 @default.
• W2080686927 hasConcept C127413603 @default.
• W2080686927 hasConcept C13965031 @default.
• W2080686927 hasConcept C155574463 @default.
• W2080686927 hasConcept C178790620 @default.
• W2080686927 hasConcept C185039092 @default.
• W2080686927 hasConcept C185592680 @default.
• W2080686927 hasConcept C192562407 @default.
• W2080686927 hasConcept C203036418 @default.
• W2080686927 hasConcept C39519442 @default.
• W2080686927 hasConcept C42360764 @default.
• W2080686927 hasConcept C56052488 @default.
• W2080686927 hasConcept C8010536 @default.
• W2080686927 hasConcept C88380143 @default.
• W2080686927 hasConcept C97355855 @default.
• W2080686927 hasConceptScore W2080686927C121332964 @default.
• W2080686927 hasConceptScore W2080686927C127413603 @default.
• W2080686927 hasConceptScore W2080686927C13965031 @default.
• W2080686927 hasConceptScore W2080686927C155574463 @default.
• W2080686927 hasConceptScore W2080686927C178790620 @default.
• W2080686927 hasConceptScore W2080686927C185039092 @default.
• W2080686927 hasConceptScore W2080686927C185592680 @default.
• W2080686927 hasConceptScore W2080686927C192562407 @default.
• W2080686927 hasConceptScore W2080686927C203036418 @default.
• W2080686927 hasConceptScore W2080686927C39519442 @default.
• W2080686927 hasConceptScore W2080686927C42360764 @default.
• W2080686927 hasConceptScore W2080686927C56052488 @default.
• W2080686927 hasConceptScore W2080686927C8010536 @default.
• W2080686927 hasConceptScore W2080686927C88380143 @default.
• W2080686927 hasConceptScore W2080686927C97355855 @default.
• W2080686927 hasIssue "1-2" @default.
• W2080686927 hasLocation W20806869271 @default.
• W2080686927 hasLocation W20806869272 @default.
• W2080686927 hasOpenAccess W2080686927 @default.
• W2080686927 hasPrimaryLocation W20806869271 @default.
• W2080686927 hasRelatedWork W1548144652 @default.
• W2080686927 hasRelatedWork W1971760344 @default.
• W2080686927 hasRelatedWork W2005165574 @default.
• W2080686927 hasRelatedWork W2046158925 @default.
• W2080686927 hasRelatedWork W2065212154 @default.
• W2080686927 hasRelatedWork W2093113994 @default.
• W2080686927 hasRelatedWork W2469380993 @default.
• W2080686927 hasRelatedWork W2592880937 @default.
• W2080686927 hasRelatedWork W2886952586 @default.

• next